Sai Life Sciences (SAILIFE) Fundamentals 2026 — P/E 75.3x, Revenue Analysis | SniperIQ
Sai Life Sciences (SAILIFE) is a India-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ₹26,546 Crore, trading at ₹1250.50 on the NSE. This SniperIQ fundamentals page covers Sai Life Sciences's valuation (P/E 75.3x, P/B 10.6x), profitability (net margin 15.9%), revenue (₹2,192 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sai Life Sciences's market cap?
Sai Life Sciences (SAILIFE) has a market capitalization of approximately ₹26,546 Crore, trading at ₹1250.50 on the NSE. Market cap moves with the live share price.
What is Sai Life Sciences's P/E ratio?
Sai Life Sciences's trailing twelve-month P/E ratio is 75.3x, with a price-to-book (P/B) of 10.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sai Life Sciences?
Sai Life Sciences runs a net profit margin of 15.9%, a gross margin of 36.9%, and an operating margin of 21.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sai Life Sciences generate?
Sai Life Sciences reported revenue of ₹2,192 Crore for fiscal year 2025, with net income of ₹349 Crore and earnings per share (EPS) of 16.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sai Life Sciences pay a dividend?
Sai Life Sciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sai Life Sciences financially healthy?
Sai Life Sciences carries a debt-to-equity ratio of 0.12x and a current ratio of 1.69x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sai Life Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sai Life Sciences (SAILIFE) the key facts are: market cap ₹26,546 Crore, P/E 75.3x, revenue ₹2,192 Crore, 52-week range 778.5-1300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sai Life Sciences's full fundamentals live
Get Sai Life Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.